Mirikizumab with surgery for Crohn's perianal fistulas
Treatments studied
Part of Digestive system clinical trials.
This study tests a combination of a drug called mirikizumab and a surgical procedure (curettage and closure) for people with Crohn's disease who have an active perianal fistula. The goal is to see if this treatment helps heal the fistula better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with Crohn's disease for at least 3 months.
- You have an active draining complex perianal fistula.
- You are able to give informed consent.
- You do not have any of the following: a rectovaginal fistula, only a simple fistula, severe rectal inflammation, a stoma, active tuberculosis, active hepatitis B, a serious infection, or are not pregnant.
- You have not participated in another investigational drug trial recently.
- You are able to undergo an MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests mirikizumab to reduce inflammation and symptoms in children with Crohn’s disease that is currently active. It may help if your Crohn’s has not improved enough (or stopped working) with at least one other Crohn’s medicine.
This trial tests a medication called Mirikizumab for adults over 60 with moderate to severe Crohn's disease or ulcerative colitis. It aims to see if the drug is safe and effective for older adults with these conditions.
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
This trial tests two study drugs, mirikizumab and tirzepatide, in people with moderate to severe Crohn's disease who also have overweight or obesity. The goal is to see if these treatments can help control Crohn's symptoms and inflammation.
This trial tests if mirikizumab can reduce deep inflammation in the intestine walls in people with active Crohn's disease. It may help heal damage that shows up on an MRI scan.
This trial tests if mirikizumab can help people with chronic inflammation of the pouch (a surgically created internal reservoir) that doesn't respond well to antibiotics or acts like Crohn's disease. It aims to see if the drug can reduce symptoms like urgency, pain, and bleeding.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.